Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge
NCT00373412
Completed
Objectives of this trial are to: Evaluate the kinetics and magnitude of the CMV-specific immune response post-Towne challenge (3000 pfu) in healthy CMV-seronegative volunteers who receive VCL CT02 administered (1 mg weekly x 3) 3 months previously compared to randomized controls who do not receive VCL CT02 as measured by: 1. antibody titers for gB; 2. T-cell IFN-g ELISPOT; 3. T-cell proliferation assays for IE1, pp65, and/or gB; and 4. cytokine and phenotypic flow cytometry responses to pp65,... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
05/05/2008
Locations: UCSF Positive Health Program, 995 Potrero, 4th Floor, San Francisco, California
Conditions: Cytomegalovirus Infection
Register for Updates
Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer
NCT00098917
Terminated
RATIONALE: Vaccines made from a person's tumor cells and white blood cells may make the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients who are undergoing surgery for stage IB, stage II, or stage IIIA non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2008
Locations: Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California
Conditions: Lung Cancer
Register for Updates
Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia
NCT00116467
Completed
The purpose of this study is to evaluate clinical and laboratory safety associated with the administration of GVAX leukemia vaccine and to determine the feasibility of generation of GVAX leukemia vaccine in subjects with acute myelogenous leukemia (AML).
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
12/18/2007
Locations: University of California, San Francisco, San Francisco, California +3 locations
Conditions: Acute Myelogenous Leukemia
Register for Updates
A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers
NCT00002261
Completed
To determine the physiological and immunological responses in healthy HIV seronegative adult volunteers vaccinated with a) the HIVAC-1e (vaccinia-HIV) vaccine expressing the envelope glycoproteins of HIV and b) the Wyeth smallpox vaccine. The parameters to be studied will include: 1. The course of physiological responses to vaccination, including (a) lesion development, progression, and resolution; (b) physiological changes such as temperature, malaise, itching at the site, etc. and (c) any obs... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
09/24/2007
Locations: Bristol - Myers Squibb Co, Wallingford, Connecticut
Conditions: HIV Infections
Register for Updates
Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and Over
NCT00232947
Completed
The goal of this study is to determine whether the immune responses induced by Fluviral, the investigational vaccine, are comparable to those induced by Fluzone, which is an influenza vaccine currently licensed in the U.S. The study focuses on persons 50 years old and over. In addition, the study will compare the rate of reactions to the two vaccines, and the general health of persons who receive them over the 42 days after immunization.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
01/19/2007
Locations: University Clinical Research, Inc., Pembroke Pines, Florida +9 locations
Conditions: Influenza
Register for Updates
Study to Eliminate Hib Carriage in Rural Alaska Native Villages
NCT00153556
Completed
Hib disease rates in rural Alaska before introduction of HIb conjugate vaccine were among the highest in the world. Since vaccine introduction, rates have fallen by 90% but the disease has not been eliminated. This study is designed to test one possible means of eliminating Hib carriage and thus to eliminate person to person transmission and invasive disease. The objective of this study is to evaluate the effectiveness of community-wide use of Hib conjugate vaccine for eliminating oropharyngeal... Read More
Gender:
ALL
Ages:
0 years and above
Trial Updated:
09/08/2005
Locations: CDC Arctic Investigations Program, Anchorage, Alaska
Conditions: Haemophilus Influenzae Type B, Carrier State
Register for Updates
A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects
NCT00002428
Completed
To evaluate the safety and immunogenicity of a combination of microparticulate monovalent HIV-1 MN synthetic branched peptide candidate vaccine for oral administration and monovalent HIV-1 MN synthetic branched peptide vaccine in alum for intramuscular administration in intermediate or higher risk HIV-negative volunteers.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
06/23/2005
Locations: Univ of California at San Francisco Gen Hosp, San Francisco, California
Conditions: HIV Infections
Register for Updates